Oct 12 close
Xenon Pharmaceuticals fell sharply this week, with shares hitting a 52-week low of $36.06 on 7 October amid a voluntary pause in new patient enrollment for azetukalner (AZK) studies, a move that has drawn law firm investigations from SBS Law and Wolf Popper on behalf of investors. Against this backdrop, the company's Q2 2026 earnings call highlighted $1.2 billion in cash extending operations into 2029 and reaffirmed plans to submit the AZK NDA for focal seizures this quarter following a successful pre-NDA FDA meeting. Guggenheim assumed coverage with a Buy rating and a $73.00 price target, and President Ian Mortimer purchased $1.1 million worth of stock, an 88% increase in his holding.
XENE closed at $35.81, down 1.7%, with its price sitting below both the 50-day average of $53.09 and the 200-day average of $52.87. The stock's one-month return stands at -38.9% and its three-month return at -46.8%. The GekkoIndex reads 68.5, placing it in the Accumulation zone, while the gap to Gekko Fair Value of $55.85 stands at -35.9%.
Earnings are scheduled for 2 November, 21 days away, falling inside a typical 20-trading-day holding window and historically producing an average absolute reaction of 6%. Over the last 90 days, insiders made 2 open-market purchases totaling $1,681,140. Seasonality over the next 20 trading days has averaged 1.8% across 5 years, rising in 3 of them. Analyst sentiment across 15 firms shows 14 Buy ratings, 1 Hold, and a consensus target of $73.37.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Xenon Pharmaceuticals scores 4 supportive, 1 mixed and 1 headwind across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed1 headwind
Averages disagree
Close $35.81 sits between the 50-day ($53.09) and 200-day ($52.87) averages, or the averages disagree.
See the chart68.5, Accumulation
Reading 68.5 is in the Accumulation zone.
See the GekkoIndex35.9% below
Price is 35.9% below Gekko Fair Value (more than 5% below).
See fair valueLeans bullish
Last 90 days: 2 open-market insider purchases.
See smart moneyReports in 21 days
Reports on Nov 2, 2026, 21 days away — inside a typical 20-trading-day hold.
See earnings+1.8% on average
From this point in the calendar, the next 20 trading days averaged +1.8% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Xenon Pharmaceuticals closed at $35.81 on Oct 12, 2026, −13.3% over the past year, inside a 52-week range of $35.06 to $72.66.
Use the left and right arrow keys to read daily values.
Put XENE on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Xenon Pharmaceuticals works on medicines for people with neurological conditions, developing drug candidates rather than selling approved products. Its pipeline includes several compounds aimed at channels in the nervous system: one targets a form of epilepsy linked to KCNQ2 and has reached Phase III testing, while others acting on potassium, sodium and calcium channels are being studied in Phase II trials for epilepsy and related disorders. The company is known for this focus on channel-targeted therapies for seizure and pain conditions.
Rather than working alone on every program, Xenon pairs its own research with outside partnerships. It has a licensing and development arrangement with Neurocrine Biosciences covering epilepsy treatments, and it works with Flexion Therapeutics on a sodium-channel inhibitor intended for pain following surgery. These collaborations sit alongside the compounds it continues to advance through its own clinical trials.
The company is headquartered in Burnaby, Canada, and traces its founding to 1996. Its shares are listed on the NASDAQ under the ticker XENE.
Xenon Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 68.5, in the Accumulation zone, down 2.2 points over five sessions.
Down 2.2 points over five sessions, from the Buying zone.
Reading for Oct 12, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 27 | +1.2% | +14.2% | ||
| Accumulation (current zone) | 252 | +0.1% | +1.7% | ||
| Neutral | 374 | −0.1% | −0.8% | ||
| Distribution | 28 | +1.1% | −2.1% | ||
| Selling | 1 | Too few readings yet | |||
Average XENE share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
Xenon Pharmaceuticals trades 35.9% below Gekko Fair Value of $55.85, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Xenon Pharmaceuticals shares are worth, recalculated every trading day.
$55.85
Gekko Fair Value, Oct 10, 2026
35.9% Undervalued
At the end of Aug 2026 the price was 19.7% below the estimate.
Insiders filed 2 open-market purchases in Xenon Pharmaceuticals worth $1.68M, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
$1.68Min 2 open-market purchases
| Filed | Insider | Type | Value |
|---|---|---|---|
| Oct 1 | MORTIMER IAN director, officer: PRESIDENT & CEO | Purchase | $1.12M |
| Oct 1 | Kelly Thomas Patrick officer: Chief Financial Officer | Purchase | $560K |
From Form 4 filings, dated to when each was filed.
No trades in XENE were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
1of the funds Gekko tracks holds XENE.
Xenon Pharmaceuticals reports on Nov 2, 2026, after the close (21 days away), and beat the EPS estimate in 5 of its last 8 reports.
Nov 2, 2026
Expected after the close, 21 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | −$1.11 est −$1.14 | — est $1.67M | −1.5% |
| May 7, 2026 | −$1.17 est −$1.17 | — est $1.36M | −3.7% |
| Feb 26, 2026 | −$1.31 est −$1.19 | — est −$179K | −3.0% |
| Nov 3, 2025 | −$1.15 est −$1.16 | — | −6.8% |
| Aug 11, 2025 | −$1.07 est −$1.03 | — | +7.7% |
| May 12, 2025 | −$0.83 est −$0.94 | $7.50M est $1.91M | −15.5% |
| Feb 27, 2025 | −$0.84 est −$0.89 | — est $313K | −5.3% |
| Nov 12, 2024 | −$0.81 est −$0.82 | — est $294K | −4.8% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Xenon Pharmaceuticals is $73.37, +104.9% from the last close, from 15 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 15 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 5 | Guggenheim | $73 | +103.9% |
| Oct 1 | RBC Capital | $70 | +95.5% |
| Sep 19 | J.P. Morgan | $82 | +129.0% |
| Sep 18 | William Blair | — | — |
| Sep 18 | H.C. Wainwright | $74 | +106.6% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Oct 10, Xenon Pharmaceuticals averaged +1.8% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +1.4% | 3 of 5 |
| Next 10 trading days | −0.1% | 3 of 5 |
| Next 15 trading days | +1.6% | 4 of 5 |
| Next 20 trading days | +1.8% | 3 of 5 |
| Next 30 trading days | −6.0% | 1 of 5 |
For scale, XENE’s typical 20-trading-day move in either direction is about 7%.
Xenon Pharmaceuticals’s market cap is $3.46B and revenue of $0 over the last twelve months.
Coverage of Xenon Pharmaceuticals this week reads positive: 4 positive, 1 neutral and 3 negative headlines.
Xenon Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 14.7% above |
| JNJJohnson & Johnson | Neutral | 3.2% below |
| ABBVAbbVie | Distribution | 28.2% above |
| MRKMerck | Neutral | 8.0% below |
| AZNAstraZeneca | Accumulation | 41.7% below |
| PFEPfizer | Neutral | 8.0% below |
A peer links to its own page where one exists.
Xenon Pharmaceuticals’s market cap is $3.46B at the Oct 12, 2026 close of $35.81, with 96.84M shares outstanding.
The consensus analyst 12-month price target for Xenon Pharmaceuticals is $73.37, +104.9% from the last close. Of the 15 firms that rated the stock in the last 90 days, 14 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Xenon Pharmaceuticals is undervalued: the Oct 12, 2026 close of $35.81 is 35.9% below Gekko Fair Value of $55.85. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Xenon Pharmaceuticals is expected to report on Nov 2, 2026, after the market closes (21 days away). Analysts expect earnings of −$1.13 per share on revenue of $1.33M. Xenon Pharmaceuticals beat the earnings estimate in 5 of its last 8 reports, moving 6% on average across the report.
Xenon Pharmaceuticals’s 52-week high is $72.66 and its 52-week low is $35.06; it closed at $35.81 on Oct 12, 2026, −13.3% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (gekkoindex, fair value, smart money and seasonality), 1 as mixed (trend) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.